What is Theravance Biopharma's investing cash flow?

Theravance Biopharma (TBPH) reported investing cash flow of $52.59M in Q1 2026.

How has Theravance Biopharma's investing cash flow changed year-over-year?

Theravance Biopharma's investing cash flow increased by 71.7% year-over-year, from $30.63M to $52.59M.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Theravance Biopharma TBPH Investing Cash Flow

Investing Cash Flow at other companies

Zevra Therapeutics, Inc.ZVRA

$79.62M+655%

LQD

Liquidia CorporationLQDA

-$2.83M-758%

Royalty PharmaRPRX

-$477.87M-195%

United TherapeuticsUTHR

$743.7M+552%

Aurinia PharmaceuticalsAUPH

-$18.08M-158%

PrecigenPGEN

$20.97M+425%

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$890.32M+67.5%

Enterprise value$642.72M+37.0%

P/E7.8×—

P/S8.1×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's investing cash flow?: Theravance Biopharma (TBPH) reported investing cash flow of $52.59M in Q1 2026.
How has Theravance Biopharma's investing cash flow changed year-over-year?: Theravance Biopharma's investing cash flow increased by 71.7% year-over-year, from $30.63M to $52.59M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.